Literature DB >> 15604441

Specificity of serum neutralizing antibodies induced by transient immune suppression of inapparent carrier ponies infected with a neutralization-resistant equine infectious anemia virus envelope strain.

Laryssa Howe1, Jodi K Craigo2, Charles J Issel3, Ronald C Montelaro2,1.   

Abstract

It has been previously reported that transient corticosteroid immune suppression of ponies experimentally infected with a highly neutralization resistant envelope variant of equine infectious anemia virus (EIAV), designated EIAV(DeltaPND), resulted in the appearance of type-specific serum antibodies to the infecting EIAV(DeltaPND) virus. The current study was designed to determine if this induction of serum neutralizing antibodies was associated with changes in the specificity of envelope determinants targeted by serum antibodies or caused by changes in the nature of the antibodies targeted to previously defined surface envelope gp90 V3 and V4 neutralization determinants. To address this question, the envelope determinants of neutralization by post-immune suppression serum were mapped. The results demonstrated that the neutralization sensitivity to post-immune suppression serum antibodies mapped specifically to the surface envelope gp90 V3 and V4 domains, individually or in combination. Thus, these data indicate that the development of serum neutralizing antibodies to the resistant EIAV(DeltaPND) was due to an enhancement of host antibody responses caused by transient immune suppression and the associated increase in virus replication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15604441     DOI: 10.1099/vir.0.80374-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Envelope variation as a primary determinant of lentiviral vaccine efficacy.

Authors:  Jodi K Craigo; Baoshan Zhang; Shannon Barnes; Tara L Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-10       Impact factor: 11.205

2.  Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses.

Authors:  Sandra D Taylor; Steven R Leib; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

3.  Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus.

Authors:  Jodi K Craigo; Corin Ezzelarab; Ronald C Montelaro
Journal:  J Virol Methods       Date:  2012-07-20       Impact factor: 2.014

4.  Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.

Authors:  Tara L Tagmyer; Jodi K Craigo; Sheila J Cook; Deborah L Even; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

Review 5.  Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity.

Authors:  Jodi K Craigo; Ronald C Montelaro
Journal:  Viruses       Date:  2013-12-02       Impact factor: 5.048

6.  Envelope determinants of equine lentiviral vaccine protection.

Authors:  Jodi K Craigo; Corin Ezzelarab; Sheila J Cook; Liu Chong; David Horohov; Charles J Issel; Ronald C Montelaro
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.